{"id":70866,"date":"2026-07-29T18:13:09","date_gmt":"2026-07-29T10:13:09","guid":{"rendered":"https:\/\/flcube.com\/?p=70866"},"modified":"2026-07-29T18:13:10","modified_gmt":"2026-07-29T10:13:10","slug":"changchun-high-tech-industries-subsidiary-gensci-advances-graves-disease-therapy-to-phase-ii-with-us-partner-yarrow-bioscience","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70866","title":{"rendered":"Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience"},"content":{"rendered":"\n

Changchun High-Tech Industries (Group) Co., Ltd.<\/strong> (SHE: 000661<\/a>) announced that its subsidiary GenSci<\/strong> has initiated an overseas Phase II clinical trial<\/strong> for Graves’ disease (GD)<\/strong> with or without thyroid eye disease (TED)<\/strong> using its first out-licensed pipeline asset, GenSci098 (YB-101)<\/strong>. The first patient has been successfully dosed in the study, which is being conducted by GenSci’s US partner Yarrow Bioscience, Inc.<\/strong> (NASDAQ: YARW<\/a>).<\/p>\n\n\n\n

Clinical Development Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Sponsor<\/strong><\/td>Yarrow Bioscience, Inc. (NASDAQ: YARW)<\/td><\/tr>
Drug Candidate<\/strong><\/td>GenSci098 (YB-101)<\/td><\/tr>
Indication<\/strong><\/td>Graves’ disease (GD) with or without thyroid eye disease (TED)<\/td><\/tr>
Trial Design<\/strong><\/td>Randomized, blinded, placebo-controlled Phase 2a\/2b study<\/td><\/tr>
Milestone<\/strong><\/td>First patient dosed<\/td><\/tr>
Data Readout<\/strong><\/td>Phase 2a proof-of-concept data expected H2 2027<\/td><\/tr>
Licensing Agreement<\/strong><\/td>Exclusive overseas rights granted to Yarrow Bio in December 2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n